GlassScriptPhysician profile
Edward W Timinski
NPI 1083140016
$14,909.94
in general payments reported to CMS, 2019-2025
18 companies · $680 in 2025
The $680 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $6,277 · 2022: $4,475 · 2023: $2,603 · 2024: $875 · 2025: $680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,157.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $9,803.94 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $969.26 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $932.21 | 2022-2024 | Austedo Xr, Uzedy, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $610.78 | 2022-2025 | Caplyta |
| Abbvie INC. | $593.28 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $289.75 | 2022-2024 | Spravato, Invega Sustenna |
| Neurocrine Biosciences, INC. | $259.88 | 2022-2024 | Ingrezza |
| Alkermes, INC. | $258.73 | 2022-2023 | Aristada, Lybalvi, Vivitrol |
| Lundbeck LLC | $255.64 | 2023-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $242.01 | 2022-2023 | Trintellix |
| Corium, LLC | $237.14 | 2022-2023 | Azstarys, Azstarys |
| Axsome Therapeutics, INC. | $157.42 | 2023-2025 | Auvelity, Sunosi |
| E.R. Squibb & Sons, L.L.C. | $116.34 | 2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $60.97 | 2022-2023 | Quviviq |
| Vertical Pharmaceuticals, LLC | $42.29 | 2024 | Relexxii |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $29.96 | 2022 | |
| Vanda Pharmaceuticals INC. | $29.78 | 2023 | Hetlioz, Fanapt |
| Eisai INC. | $20.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Timinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.